Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Centenarians Have Fewer Diseases, Develop Them More Slowly
FRIDAY, Aug. 15, 2025 -- Centenarians have lower overall disease burden, delayed onset of multiple conditions, and fewer cooccurring diseases over time...
FDA Approves Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the Treatment of Fibromyalgia
CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced...
High Metabolic Syndrome Severity Linked to Development of CKD
FRIDAY, Aug. 15, 2025 -- High metabolic syndrome (MetS) severity, expressed by the continuous metabolic syndrome severity score (cMetS-S), is associated with...
Autoimmune Diseases Linked to Digestive System Cancers
FRIDAY, Aug. 15, 2025 -- Autoimmune diseases are associated with certain digestive system cancers, according to a review published in the September issue of...
Opportunistic Community Screening IDs Uncontrolled Cardiovascular Risk Factors
FRIDAY, Aug. 15, 2025 -- Opportunistic pop-up community screening identifies a high prevalence of uncontrolled cardiovascular risk factors, according to a...
Hypoglossal Nerve Stimulator Implantation Safe for OSA in Children With Down Syndrome
FRIDAY, Aug. 15, 2025 -- For children aged younger than 13 years with Down syndrome (DS) and severe obstructive sleep apnea (OSA), hypoglossal nerve stimulator...
Ladder Recall Follows Reports of Falls, Head Injuries and Broken Bones
FRIDAY, Aug. 15, 2025 — More than 122,000 ladders sold at Home Depot are being recalled because their locking mechanism can fail, putting users at risk...
New Brain Implant Could Let People Speak Just by Thinking Words
FRIDAY, Aug. 15, 2025 — For the first time, scientists have created a brain implant that can “hear” and vocalize words a person is only...
Study Finds Redlined Neighborhoods Face Delays in Emergency Care
FRIDAY, Aug. 15, 2025 — People living in neighborhoods once labeled “hazardous” on federal housing maps are still more likely to wait longer...
Cholera Outbreak in Darfur Kills 40 in One Week, Officials Say
FRIDAY, Aug. 15, 2025 — A fast-moving cholera outbreak in Sudan’s Darfur region has killed 40 people and sickened more than 2,300 in the past week...
Source Of Breathing Problems Identified For People With Spinal Cord Injuries
FRIDAY, Aug. 15, 2025 — Breathing problems are common among people with a spinal cord injury, frequently contributing to illness and death. But...
FDA Approves Brinsupri (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-...
FDA Grants Accelerated Approval to Hernexeos (zongertinib) for Previously Treated Patients with HER2-Mutant Advanced NSCLC
Ridgefield, Conn., U.S. and Ingelheim, Germany , August 8, 2025 -- Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved by the U.S...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food...
FDA Grants Accelerated Approval to Modeyso (dordaviprone) for the Treatment of Recurrent H3 K27M-Mutant Diffuse Midline Glioma
DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE...
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
SECAUCUS, N.J., July 24, 2025 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc. (PFP) announces the acceptance by U.S. Food and Drug Administration (FDA) of...
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of...
Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
SPRING HOUSE, Pa. (July 21, 2025) – Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application (NDA) to the U.S. Food...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 17, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug...
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass., August 13, 2025 – Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for...
Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP, Demonstrating Statistically Significant Improvement in Time to Treatment Failure
Basel, August 12, 2025 – Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in...
Novartis Announces Both Ianalumab Phase III Clinical Trials Met Primary Endpoint in Patients with Sjögren’s Disease
Basel, August 11, 2025 – Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology...
Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
BRAINTREE, Mass., Aug. 7, 2025 /PRNewswire/ -- Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.